2 quality healthcare options for ASX investors

Demand for healthcare services has been tipped to grow strongly in the future. Could these shares benefit?

| More on:
Rising healthcare ASX share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With populations around the world ageing and technologies and treatments improving, demand for healthcare services is expected to grow strongly over the next few decades. In light of this, the healthcare sector could be a good place to consider investing with a long term view.

But which ASX healthcare shares should you buy? Two that are rated as buys right now are listed below. Here's what you need to know about them:

Nanosonics Ltd (ASX: NAN)

Nanosonics could be a good option for investors in the healthcare sector. It is a leading infection control specialist which provides the industry-leading trophon EPR disinfection system for ultrasound probes.

If demand for healthcare services increases, there's a likelihood that ultrasound usage will increase in line with this. This, combined with further market share gains, would bode well for Nanosonics' growth over the next decade and beyond.

At present, management estimates that 80,000 patients are protected from the risk of cross contamination every day because the ultrasound probe has been high-level disinfected with trophon. This is driving strong recurring revenue growth from the consumable products the system requires.

Positively, management isn't resting on its laurels and is aiming to launch several new technologies that are targeting unmet needs. These are believed to have similar addressable markets to the trophon product. If successful, this could provide Nanosonics with a significant runway for growth, especially in a post-pandemic world heavily focused on infection prevention.

Analysts at UBS are positive on the company. They currently have a buy rating and $7.20 price target on its shares.

Pro Medicus Limited (ASX: PME)

Another healthcare share to consider is Pro Medicus. It is a healthcare technology company that provides healthcare organisations with radiology information systems, picture archiving and communication systems, and advanced visualisation solutions.

Pro Medicus has been a positive performer again in FY 2021 despite the pandemic. In February, the company reported a 7.8% increase in revenue to $31.6 million and a 25.9% jump in underlying profit before tax to $18.76 million.

Since then, the company has won a number of lucrative long term contracts with major healthcare institutions. In addition to this, it still has a large pipeline of sales opportunities that could be converted in the near future.

And thanks to the quality of the company's technology and the structural shift away from legacy systems, Pro Medicus appears very well positioned for growth over the long term. This could be bolstered by its recent collaboration with healthcare giant Mayo Clinic.

That agreement will serve as the framework for collaboration between the two parties to facilitate development and commercialisation in the field of artificial intelligence (AI), leveraging the company's Visage AI Accelerator platform.

In response to the news, Goldman Sachs retained its buy rating and $53.80 price target on the company's shares. It commented: "We believe the strategy of partnering with the leading academics helps to maximise the value and competitive advantage of PME's technology proposition."

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »